AAO 2024: Reduction in IOP after switching to latanoprostene bunod in glaucoma patients in real-world clinical practice

Constance O. Okeke, MD, shared insights from on her presentation entitled, "Reduction in IOP after switching to latanoprostene bunod in glaucoma patients in real-world clinical practice," which was given at the American Academy of Ophthalmology held in Chicago, Illinois.

This transcript has been lightly edited for clarity.

Constance O. Okeke, MD: Hello. My name is Dr Constance Okeke. I'm coming from Norfolk, Virginia, at Virginia Eye Consultants, Eye Care Partners. Today, I'm sharing the results of a poster that's entitled, "The reduction of intraocular pressure when switching to latanoprostene bunod in a real-world practice setting." We looked at IRIS registry data that was paired with claims data, and we were able to sift down to 833 patients, who had been switched to latanoprostene bunod, when they were previously on either a non-PGA or a combination therapy.

What we were able to find is in that the overall cohort, there was about a 2.8 millimeters of mercury reduction in the mean IOP from the baseline IOP of 19.5 this was significant, and it was also something that we saw when looking at the absolute pressures, there was about 30 to 34% of patients who had at least a 5 millimeter mercury or more IOP reduction in absolute numbers, and so this is an exciting finding. It goes along with some other studies that we've been involved in supporting that when switching to latanoprostene bunod, there can be a significant reduction of pressure. And this could be very beneficial in patients who were on non-PGAs that were on maybe 2 or 3 times a day, switching to LBN, just latanoprostene bunod, but not just once a day, and having a significant reduction in pressure and also reducing the compliance issues.

Now, one of the surprises that we noticed was that the patients who were on non-PGA combination therapy, they did the best in terms of their reduction and that, again, this is really exciting for us to see, because patients who are non-PGA combination therapy usually take those medications 2 to 3 times a day, so being able to switch to latanoprostene bunod monotherapy, that would also allow them to not have just a reduction in eye pressure, but also an improved quality of life, which helps with compliance issues.